Liposomal amphotericin B for the treatment of Nepalese patients with visceral leishmaniasis.
Efficacy and safety of liposomal amphotericin B in Nepalese patients with visceral leishmaniasis.
The United Nations Children's Fund (UNICEF)/ The United Nations Development Programme (UNDP) /World Bank /World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases (TDR)
35 participants
Apr 1, 2010
Interventional
Conditions
Summary
Liposomal preparation of amphotericin B is found to have good efficacy (>97%) against visceral leishmaniasis in India. As there is there is no information about the use of liposomal amphotericin B in Bangladesh, this study is proposed to determine the efficacy and safety of liposomal amphotericin B in the treatment of visceral leishmaniasis in Nepalese patients. Fifthy patients will be enrolled to receive a dose of 3 mg/kg of liposomal amphotericin B for 5 consecutive days (total dose 15mg/kg) with regard to final cure rate at six months after the end of treatment.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Liposomal amphotericin B 3mg/kg/intravenously for 5 consecutive days (total dose 15mg/kg)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000130066